|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAH17 |
Gene summary for DNAH17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAH17 | Gene ID | 8632 |
| Gene name | dynein axonemal heavy chain 17 | |
| Gene Alias | DNAHL1 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8632 | DNAH17 | LZE4T | Human | Esophagus | ESCC | 2.37e-02 | 1.31e-01 | 0.0811 |
| 8632 | DNAH17 | LZE21T | Human | Esophagus | ESCC | 6.52e-03 | 2.77e-01 | 0.0655 |
| 8632 | DNAH17 | P2T-E | Human | Esophagus | ESCC | 4.16e-22 | 4.43e-01 | 0.1177 |
| 8632 | DNAH17 | P15T-E | Human | Esophagus | ESCC | 2.04e-07 | 2.20e-01 | 0.1149 |
| 8632 | DNAH17 | P17T-E | Human | Esophagus | ESCC | 1.49e-05 | 2.69e-01 | 0.1278 |
| 8632 | DNAH17 | P20T-E | Human | Esophagus | ESCC | 1.73e-12 | 3.47e-01 | 0.1124 |
| 8632 | DNAH17 | P21T-E | Human | Esophagus | ESCC | 3.75e-03 | 1.03e-01 | 0.1617 |
| 8632 | DNAH17 | P24T-E | Human | Esophagus | ESCC | 7.98e-13 | 3.55e-01 | 0.1287 |
| 8632 | DNAH17 | P27T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.52e-01 | 0.1055 |
| 8632 | DNAH17 | P28T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.40e-01 | 0.1149 |
| 8632 | DNAH17 | P31T-E | Human | Esophagus | ESCC | 6.56e-15 | 3.13e-01 | 0.1251 |
| 8632 | DNAH17 | P32T-E | Human | Esophagus | ESCC | 1.61e-32 | 6.26e-01 | 0.1666 |
| 8632 | DNAH17 | P36T-E | Human | Esophagus | ESCC | 7.95e-23 | 7.83e-01 | 0.1187 |
| 8632 | DNAH17 | P37T-E | Human | Esophagus | ESCC | 4.78e-22 | 5.83e-01 | 0.1371 |
| 8632 | DNAH17 | P40T-E | Human | Esophagus | ESCC | 8.35e-06 | 2.32e-01 | 0.109 |
| 8632 | DNAH17 | P42T-E | Human | Esophagus | ESCC | 2.62e-05 | 2.42e-01 | 0.1175 |
| 8632 | DNAH17 | P47T-E | Human | Esophagus | ESCC | 2.02e-06 | 1.66e-01 | 0.1067 |
| 8632 | DNAH17 | P49T-E | Human | Esophagus | ESCC | 7.97e-13 | 7.21e-01 | 0.1768 |
| 8632 | DNAH17 | P52T-E | Human | Esophagus | ESCC | 1.76e-12 | 2.37e-01 | 0.1555 |
| 8632 | DNAH17 | P62T-E | Human | Esophagus | ESCC | 1.85e-29 | 6.08e-01 | 0.1302 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAH17 | SNV | Missense_Mutation | rs778235719 | c.11902N>A | p.Ala3968Thr | p.A3968T | Q9UFH2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
| DNAH17 | SNV | Missense_Mutation | c.1951N>T | p.Asp651Tyr | p.D651Y | Q9UFH2 | protein_coding | deleterious(0.04) | probably_damaging(0.96) | TCGA-A2-A04X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DNAH17 | SNV | Missense_Mutation | rs750434977 | c.8755N>A | p.Glu2919Lys | p.E2919K | Q9UFH2 | protein_coding | deleterious(0.03) | benign(0.376) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| DNAH17 | SNV | Missense_Mutation | novel | c.11200N>T | p.Val3734Phe | p.V3734F | Q9UFH2 | protein_coding | deleterious(0.01) | possibly_damaging(0.667) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| DNAH17 | SNV | Missense_Mutation | rs753683524 | c.8980N>A | p.Val2994Met | p.V2994M | Q9UFH2 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DNAH17 | SNV | Missense_Mutation | novel | c.2724N>G | p.Asp908Glu | p.D908E | Q9UFH2 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| DNAH17 | SNV | Missense_Mutation | novel | c.12716A>G | p.Asn4239Ser | p.N4239S | Q9UFH2 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD |
| DNAH17 | SNV | Missense_Mutation | c.8718N>C | p.Met2906Ile | p.M2906I | Q9UFH2 | protein_coding | tolerated(0.25) | benign(0) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| DNAH17 | SNV | Missense_Mutation | novel | c.10421N>A | p.Ile3474Asn | p.I3474N | Q9UFH2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| DNAH17 | SNV | Missense_Mutation | novel | c.12841N>C | p.Thr4281Pro | p.T4281P | Q9UFH2 | protein_coding | tolerated(0.12) | benign(0) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |